Effect of age and treatment on predictive value of measurable residual disease: implications for clinical management of adult patients with acute myeloid leukemia

Abstract

Measurable residual disease (MRD) is a powerful predictor of outcome in acute myeloid leukemia (AML). In the early phases of treatment, MRD refines initial disease risk stratification and is used for the allocation to allogeneic transplant (HSCT). Despite its well-established role, a relatively high fraction of patients eventually relapses albeit achieving MRDneg status. The aim of this work was to assess specifically the influence of baseline features and treatment intensity on the predictive value of an MRDneg status, particularly focusing on MRD2, measured after 2 consecutive chemotherapeutic cycles. Among baseline features, younger MRD2neg patients (<55 y) had a significantly longer DFS (median not reached) compared to their elderly counterpart (median 25.0 months, P=0.013, HR=2.08). Treatment intensity, specifically the delivery of high dose of ARA-C in induction or first consolidation, had apparently a pejorative effect on the outcome of MRD2neg patients compared to standard dose (P=0.048, HR=1.80), a finding confirmed also by the analysis of data extracted from the literature. The combination of age and treatment intensity allowed us to identify categories of patients, among those who reached a MRD2neg status, characterized by significantly different disease-free survival rate. Our data showed that variables such as age and intensity of treatment administered can impact on the predictive value of MRD in patients with AML. In addition to underscoring the need for further improvement of MRD analysis, these findings call for a reasoned application of MRD data, as currently available, to modulate consolidation therapy on adequately estimated relapse rates.